# Rocket One's Hoth Therapeutics Reports Strong HT-001 Efficacy Results, Ends Phase 2a Early and Plans to Pursue Phase 3 to Bring Treatment to Cancer Patients

- Source: PR Newswire M&A
- Published: 2026-11-03T13:17:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/rocket-ones-hoth-therapeutics-reports-strong-ht-001-efficacy-results-ends-phase-2a-early-and-plans-to-pursue-phase-3-to-bring-treatment-to-cancer-patients-302927285.html
- Canonical: https://groundlevelnews.com/story/rocket-one-s-hoth-therapeutics-reports-strong-ht-001-efficacy-results--6997a0/

Positive interim findings drive early trial conclusion; Hoth prepares to seek FDA alignment on a potential pivotal study for cancer treatment–related skin toxicity HOBOKEN, N.J., Nov. 3, 2026 /PRNewswire/ -- Rocket One Inc. (Nasdaq: RKTO) ("Rocket One" or the "Company") today announced...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._